The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Under the combination, first announced in August, Exscientia will become a wholly-owned subsidiary of Recursion, creating a trans-Atlantic AI powerhouse with a pipeline of more than 10 clinical and ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

There is a great wealth of state parks within the state of Indiana. Between preserving natural habitats and providing ...

These days, the frontier AI labs are all racing to build self-improving models. Some believe it’s the surest route to ...

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...

Assail, the pioneer in autonomous red teaming powered by recursive self-improvement AI, today announced Sidewindertm, a ...

As AI moves from experimentation to business-critical operations, leadership teams will need to look beyond pilot outcomes and technical performance.

Biopharma companies won’t fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.

Integrating humanities into AI development is vital because societal impact is shaped by those who understand meaning, not just builders.

The Pulse Report highlights AI's expanding role in drug discovery, biomarker identification, clinical trial optimization and ...